Merck KGaA in Advanced Talks to Acquire SpringWorks Therapeutics in Potential $4 Billion Deal

Merck KGaA (MRCG.DE), the German healthcare and technology powerhouse, announced on Monday that it is in advanced negotiations to acquire U.S. biotech firm SpringWorks Therapeutics (SWTX.O), known for its focus on cancer and rare diseases. This move could significantly bolster Merck's oncology portfolio, especially following recent setbacks in its late-stage drug trials.

In a statement, Merck confirmed that discussions are ongoing but noted that no legally binding agreement has been reached, and the outcome remains uncertain. The talks follow an earlier report from Reuters, which indicated that a deal could be finalized in the coming weeks, with sources requesting anonymity due to the confidential nature of the negotiations.

SpringWorks shares soared 34% on Monday, pushing the company's market value to approximately $4 billion. The stock initially jumped nearly 49% after news of the talks broke, reaching its highest levels since April 2022. However, shares of Merck KGaA closed down 3.7% amid broader market fluctuations.

The U.S. healthcare sector is witnessing a resurgence in deal-making activity after a slowdown in 2024, largely due to pharmaceutical companies focusing on integrating past acquisitions. For example, Johnson & Johnson recently agreed to acquire Intra-Cellular Therapeutics for about $14.6 billion.

SpringWorks, based in Stamford, Connecticut, is a commercial-stage biotech company that develops treatments for various cancers, particularly rare tumors and uterine cancer. Its drug for treating desmoid tumors has already received U.S. approval, and it anticipates another approval for a product addressing neurofibromatosis type-1 later this month.

Should the acquisition succeed, it would represent one of Merck's largest pharmaceutical transactions in recent years, enhancing its cancer treatment pipeline at a crucial time. The company has faced significant challenges, including halting development on its Xevinapant drug for head and neck cancer and experiencing failures in trials for its Evobrutinib multiple sclerosis treatment.

Analysts at JPMorgan expressed optimism regarding the potential acquisition, noting that it could complement Merck’s existing oncology operations, which account for about 25% of its healthcare sales in 2024. They believe that the products offered by SpringWorks could counterbalance the impact of competition and loss of exclusivity that Merck is currently facing.

Merck has a history of ambitious acquisitions, including its $17 billion purchase of Sigma-Aldrich in 2015 and the €5.8 billion acquisition of Versum in 2019. In a recent interview, Merck's CEO mentioned that improving sales growth would allow for a more cautious approach to future acquisitions, especially in a market where valuations remain high.

As the discussions progress, the pharmaceutical industry will be watching closely to see if Merck KGaA can successfully finalize this transformative deal.